淀粉样蛋白β沉积的空间范围及其与Tau-PET和认知的关联
这项纵向多中心队列研究纳入3个队列共817名基线认知未受损的参与者,按Aβ-PET结合的空间范围分为广泛沉积、区域沉积和Aβ阴性三组。区域Aβ沉积者相比Aβ阴性者APOE ε4携带比例更高、脑脊液Aβ1-42水平降低、纵向Aβ-PET累积更明显,但脑脊液磷酸化tau181、tau-PET结合及认知下降相对较少。多数区域Aβ沉积者按经典Aβ阳性阈值或视觉读片会被判为阴性。
要点
- 区域Aβ沉积者APOE ε4比例更高、脑脊液Aβ1-42更低、纵向Aβ-PET累积更明显。
- 区域Aβ沉积者脑脊液磷酸化tau181和tau-PET结合相对较少、认知下降不明显。
- 56%至100%的区域Aβ沉积者按经典Aβ阳性阈值或视觉读片会被判为阴性。
核心结论
- 区域Aβ沉积似乎具有生物学相关性,该阶段参与者脑脊液磷酸化tau181、tau-PET结合及相关认知下降相对较少,是抗淀粉样蛋白药物的理想靶点。
- 多数区域Aβ沉积者按经典Aβ阳性阈值会被判为阴性。
研究设计与样本
- 纵向多中心队列研究,纳入3个独立队列:PREVENT-AD(数据收集于2012-2020年)、ADNI(数据收集于2005-2019年)和HABS(数据收集于2011-2019年)。
- 共纳入817名参与者:PREVENT-AD 129名(平均[SD]年龄63.5[4.7]岁;33名[26%]男性;126名[98%]白人),ADNI 400名(平均[SD]年龄73.6[5.8]岁;190名[47%]男性;10名[5%]西班牙裔,338名[91%]白人),HABS 288名(平均[SD]年龄73.7[6.2]岁;117名[40%]男性;234名[81%]白人)。
- 所有参与者首次Aβ-PET扫描时认知未受损。
- 按Aβ-PET结合空间范围三级分类:广泛沉积( designated脑区均阳性)、区域沉积(部分而非全部脑区阳性)、Aβ阴性(无任何标准Aβ信号)。
主要发现
- 与Aβ阴性者相比,区域Aβ沉积者APOE ε4携带者比例更高(PREVENT-AD:18名[64%] vs 22名[27%];ADNI:34名[31%] vs 38名[19%])。
- 与Aβ阴性者相比,区域Aβ沉积者脑脊液Aβ1-42水平降低(F=24和71),纵向Aβ-PET累积更明显(显著β=0.019至0.056)。
- 广泛Aβ沉积者表现出明显认知下降(显著β=-0.014至-0.08)、脑脊液磷酸化tau181更高(F=5和27)、tau-PET结合更高(所有F>7.55)。
- 按各队列指定的Aβ阳性二分阈值或视觉读片分类,多数区域Aβ沉积者(56%至100%,取决于分类方法和队列)会被判为Aβ阴性。
关键数值与推荐
- Aβ-PET结合空间范围三级分类:广泛沉积、区域沉积、Aβ阴性。
- 区域Aβ沉积者相比Aβ阴性者APOE ε4携带比例:PREVENT-AD 64% vs 27%,ADNI 31% vs 19%。
- 区域Aβ沉积者脑脊液Aβ1-42降低(F=24和71),纵向Aβ-PET累积β=0.019至0.056。
- 广泛Aβ沉积者认知下降β=-0.014至-0.08,脑脊液磷酸化tau181升高(F=5和27),tau-PET结合升高(所有F>7.55)。
- 56%至100%的区域Aβ沉积者按经典阈值或视觉读片被判为Aβ阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preventive trials of anti-amyloid agents might preferably recruit persons showing earliest biologically relevant β-amyloid (Aβ) binding on positron emission tomography (PET). OBJECTIVE: To investigate the timing at which Aβ-PET binding starts showing associations with other markers of Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal multicentric cohort study included 3 independent cohorts: Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) (data collected from 2012-2020), Alzheimer Disease Neuroimaging Initiative (ADNI) (data collected from 2005-2019), and Harvard Aging Brain Study (HABS) (data collected from 2011-2019). In a 3-tiered categorization of Aβ-PET binding spatial extent, individuals were assigned as having widespread Aβ deposition if they showed positive signal throughout a designated set of brain regions prone to early Aβ accumulation. Those with binding in some but not all were categorized as having regional deposition, while those who failed to show any criterion Aβ signal were considered Aβ-negative. All participants who were cognitively unimpaired at their first Aβ PET scan. MAIN OUTCOMES AND MEASURES: Differences in cerebrospinal fluid (CSF), genetics, tau-PET burden, and cognitive decline. RESULTS: A total of 817 participants were included, including 129 from the PREVENT-AD cohort (mean [SD] age, 63.5 [4.7] years; 33 [26%] male; 126 [98%] White), 400 from ADNI (mean [SD] age, 73.6 [5.8] years; 190 [47%] male; 10 [5%] Hispanic, 338 [91%] White), and 288 from HABS (mean [SD] age, 73.7 [6.2] years; 117 [40%] male; 234 [81%] White). Compared with Aβ-negative persons, those with regional Aβ binding showed proportionately more APOE ε4 carriers (18 [64%] vs 22 [27%] in PREVENT-AD and 34 [31%] vs 38 [19%] in ADNI), reduced CSF Aβ1-42 levels (F = 24 and 71), and greater longitudinal Aβ-PET accumulation (significant β = 0.019 to 0.056). Participants with widespread amyloid binding further exhibited notable cognitive decline (significant β = -0.014 to -0.08), greater CSF phosphorylated tau181 (F = 5 and 27), and tau-PET binding (all F > 7.55). Using each cohort's specified dichotomous threshold for Aβ positivity or a visual read classification, most participants (56% to 100%, depending on classification method and cohort) with regional Aβ would have been classified Aβ-negative. CONCLUSIONS AND RELEVANCE: Regional Aβ binding appears to be biologically relevant and participants at this stage remain relatively free from CSF phosphorylated tau181, tau-PET binding, and related cognitive decline, making them ideal targets for anti-amyloid agents. Most of these individuals would be classified as negative based on classical thresholds of Aβ positivity.
引用
- Ozlen H, Pichet Binette A, Köbe T, et al. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition. JAMA Neurol. 2022. PMID: 35994280. doi:10.1001/jamaneurol.2022.2442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。